ArticleFrontiers in immunology2026
Molecular crosstalk between MASLD and IVDD revealed through integrated biomarker discovery analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD), recently retermed as metabolic dysfunction-associated steatotic liver disease (MASLD), and intervertebral disc degeneration (IVDD) are major health burdens with rising prevalence. Despite affecting different organ systems, emerging evidence suggests potential molecular crosstalk between these conditions. However, the underlying mechanisms remain poorly understood. Methods: We employed comprehensive bioinformatics analysis to investigate shared pathogenic mechanisms between MASLD and IVDD through integrated bulk and single-cell RNA sequencing datasets. Weighted gene co-expression network analysis and LASSO regression were used to identify common biomarkers. Experimental validation was performed using blood samples from patients and controls. Results: Transcriptomic profiling revealed distinct molecular signatures: MASLD showed enrichment in metabolic pathways (cholesterol metabolism, PPARγ signaling), while IVDD exhibited cellular signaling activation (MAPK, PI3K-AKT pathways). Four shared biomarkers were identified through LASSO regression: STAB2, RAPGEFL1, IGF1, and ZNF285. Experimental validation confirmed significant STAB2 upregulation and IGF1 downregulation in both diseases, with enhanced alterations in concurrent MASLD-IVDD patients. Through single-cell analysis of 10,388 NAFLD cells and 35,846 IVDD cells, Scissor analysis was employed to identify disease-associated cell populations and revealed two additional common biomarkers (PHACTR1 and RIPOR2), with experimental validation demonstrating significant alterations in patients with concurrent MASLD-IVDD. Furthermore, immune communication analysis identified GALECTIN as the predominant shared signaling pathway. Conclusions: This study provides preliminary evidence for molecular crosstalk between MASLD and IVDD, suggesting systemic metabolic dysfunction may influence distant tissue pathology through shared inflammatory and metabolic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.